We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 200

News Bytes - May 16, 2013

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The National Institutes of Health (NIH) Office of Biotechnology Activities proposes revising the "NIH Guidelines for Research Involving Recombinant

Biotech receives $32.5 million for cancer research

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

Celator Pharmaceuticals, Inc., a Princeton, New Jersey-based company that develops cancer therapies, has raised $32.5 million in the final closing of

NASDAQ Biotechnology Index surpasses all-time high in 1Q13

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe

EU Medicines Agency plans to appeal interim rulings on release of clinical trial data

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • May 16 2013

According to a news source, European Medicines Agency (EMA) Director Guido Rasi intends to appeal interim rulings recently issued by the European

Rapid biosimilar growth seen through 2023

  • Shook Hardy & Bacon LLP
  • -
  • Global
  • -
  • May 16 2013

British market-research firm Visiongain has forecast a $2.445-billion global market for biosimilars in 2013, a 20-percent increase over 2012, with

Putative class alleges pharma statements about new drug violated securities laws

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

Aveo Pharmaceuticals, Inc. and several of its executives have been targeted in a securities class action filed in a federal court in Massachusetts

Congress advances pharma supply chain and animal-drug user-fee laws

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The House Energy and Commerce Subcommittee on Health has reportedly approved draft legislation that would change the existing lot-level

Universities abroad experiment with no-fee licensing to drive biotech partnerships

  • Shook Hardy & Bacon LLP
  • -
  • Australia, Canada, European Union, United Kingdom, USA
  • -
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

Annual report reveals need for biotech shift in focus to demonstrate drug value

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 2 2013

According to Ernst & Young's 27th annual biotechnology industry report, the global biotechnology industry has continued its recovery, but small and

Pharmaceutical trade group reports 241 blood cancer drugs in development

  • Shook Hardy & Bacon LLP
  • -
  • Global
  • -
  • May 2 2013

The Pharmaceutical Research and Manufacturers of America (PhRMA) has released a report showing that U.S. biopharmaceutical companies have more than

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy